每经头条（nbdtoutiao）——年产量是传统大田120倍以上，1个人管理1栋楼！实探中国"植物工厂"：水 稻生产期从120天减到60天，没有虫害不用打农药 （记者 王晓波） 每经AI快讯，海正药业1月12日晚间发布公告称，公司第十届第十二次董事会会议于2026年1月12日以 通讯方式召开。会议审议了《关于浙江海正动物保健品有限公司与中誉宠物食品（漯河）有限公司共同 投资设立合资公司的议案》等文件。 ...

Group 1 - The animal vaccine sector experienced a decline of 0.04%, ranking among the top losers in the concept sector, with notable declines from companies such as Hengtong Co., BioShares, and Kanghua Bio [1] - Among the animal vaccine stocks, 9 companies saw price increases, with Dongfang Bio, KQ Bio, and Haili Bio leading the gains at 2.23%, 0.87%, and 0.77% respectively [1] - The sector faced a net outflow of 212 million yuan from main funds, with 14 stocks experiencing outflows, and 7 stocks seeing outflows exceeding 10 million yuan, led by Roniu Mountain with a net outflow of 82.38 million yuan [2] Group 2 - The top stocks with net outflows included BioShares, Hengtong Co., and Kanghua Bio, with net outflows of 41.91 million yuan, 41.77 million yuan, and 24.74 million yuan respectively [2] - Conversely, the stocks with the highest net inflows were Dabeinong, Haili Bio, and Guoyao Modern, with net inflows of 32.76 million yuan, 6.20 million yuan, and 3.24 million yuan respectively [2] - The trading data indicated that Roniu Mountain had a trading rate of 8.05% and a price drop of 1.05%, while Dongfang Bio had a trading rate of 1.46% and a price increase of 2.23% [3]

浙江海正药业股份有限公司（以下简称"公司"）第十届董事会第十二次会 议于 2026 年 1 月 12 日（周一）以通讯方式召开，应参加会议董事 9 人，亲自参 加会议董事 9 人。本次会议的召开程序符合《公司法》和《公司章程》的规定， 会议合法有效。本次会议由公司董事长肖卫红先生主持，经审议，与会董事以通 讯表决方式通过了如下决议： 一、关于浙江海正动物保健品有限公司与中誉宠物食品（漯河）有限公司 共同投资设立合资公司的议案； 公司控股子公司浙江海正动物保健品有限公司（以下简称"海正动保"）为 抓住市场机遇、加速完善动物健康非药领域的战略布局，于 2025 年 12 月 15 日 在椒江设立了全资子公司浙江海正动物营养科技有限公司（以下简称"海正营养 科技"）。基于中誉宠物食品（漯河）有限公司（以下简称"中誉宠食"）在全球 宠物食品领域的领先地位，为增进海正动保在动保领域的全面布局，依托双方资 源优势与核心能力，搭建长期稳定的宠物食品战略合作平台，同意海正动保与其 战略合作方中誉宠食共同出资设立合资公司并签署相关合资协议，具体情况如下： （一） 中誉宠食基本情况 证券代码：600267 证券简称：海正药业 公 ...

Group 1 - The company announced that its subsidiary, Haizheng Dongbao, plans to establish a joint venture with Zhongyu Pet Food, named Zhejiang Haizheng Zhongyu Animal Nutrition Technology Co., Ltd, with a registered capital of 50 million yuan [1] - Haizheng Dongbao will contribute 30 million yuan for a 60% stake, while Zhongyu Pet Food will invest 20 million yuan for a 40% stake [1] - The joint venture will focus on the pet prescription food business, and both parties have made provisions regarding capital increase and corporate governance [1] Group 2 - The company's wholly-owned subsidiary, Zhejiang Lunsing Synthetic Biotechnology Co., Ltd, has initiated an "Industrialization Synergy Upgrade Project" with a total investment of 497 million yuan [1] - The project is applying for a loan of 334 million yuan and has a construction period of 4 years [1]

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ （来源：科技行者） 作者：高飞 来CES，高通必然是一个不能错过的站点。 我给一个三段论的解释：CES的本质是消费电子展，消费电子的主要形态是终端，而要说有什么企业能 和各种类型的终端都发生关系，这家企业就是高通。 实际上，我在CES上看到的第一个有高通印记的设备，还不是在高通展台，而是在联想展台：一款叫 Project Maxwell的AI吊坠，用的就是高通的技术。 真正到了高通展台，人潮从一面墙绕到另一面，目光所及之处更是各种「终端」。所以一个自然的问题 是：这些终端有什么共通因素？来CES之前，高通组织了一场展前沟通会，高通技术公司市场高级总监 Catherine Baker用两个词概括今年的主题：个人AI和物理AI。高通技术公司产品市场副总裁Ignacio Contreras则介绍了汽车、机器人等具体业务的进展。 所谓「个人AI」，就是「以用户为中心的AI」，在你身边能看、能听、能说、能执行任务，比如智能 手机、PC、可穿戴、XR、智能家居等；所谓「物理AI」，就是「提升各行业水平的AI」，在物理世界 里能感知、能处理、能行动、 ...

Core Viewpoint - Zhejiang Haizheng Pharmaceutical Co., Ltd. (referred to as "Haizheng Pharmaceutical") announced that its subsidiary Zhejiang Borui Biopharmaceutical Co., Ltd. (referred to as "Borui Biopharma") has submitted an application for an H-share initial public offering (IPO) to the Hong Kong Stock Exchange, aiming for a listing on the main board [1]. Company Overview - Borui Biopharma focuses on immunotherapy and has integrated capabilities in research, production, and sales. Its history dates back to the biopharmaceutical division of Haizheng Pharmaceutical and was restructured into a limited liability company in January 2019 [2]. - Borui Biopharma has established a portfolio of immunotherapy products, including eight commercialized products such as the first and only approved CD20-targeting innovative drug in China, and several innovative ADC pipelines based on next-generation technology platforms [2]. Financial Performance - Borui Biopharma has shown stable revenue growth, with reported revenues of 1.257 billion yuan, 1.623 billion yuan, and 1.379 billion yuan for the years 2023, 2024, and the first nine months of 2025, respectively. The profit attributable to equity shareholders increased from 19.05 million yuan in 2023 to 122 million yuan in the first nine months of 2025 [3]. - However, the gross profit margin has been declining, with figures of 82.2%, 79.2%, and 74.4% for the years 2023, 2024, and the first nine months of 2025, respectively, reflecting a cumulative decrease of 7.8 percentage points [3]. Market Challenges - Borui Biopharma faces multiple challenges in the biopharmaceutical industry, including ongoing pressure from volume-based procurement policies and competition from other companies in the autoimmune and oncology sectors, which may lead to reduced profit margins [4]. - The company has a high customer concentration risk, with over 68% of its revenue coming from its top five clients, which amplifies operational uncertainties [4]. - The complexity of biopharmaceutical production processes poses quality control risks, and the long development cycles and high failure rates of innovative drugs present ongoing challenges to its sustainability [4]. IPO Process - Borui Biopharma's IPO process requires approvals from the China Securities Regulatory Commission, the Hong Kong Securities and Futures Commission, and the Stock Exchange, indicating that there are uncertainties in the timeline and outcome of the IPO [5].

Core Viewpoint - The stock price of Zhejiang Hai Zheng Pharmaceutical Co., Ltd. has shown a positive trend, with a year-to-date increase of 7.38% and a recent uptick in trading activity, indicating potential investor interest and market confidence in the company's performance [2]. Group 1: Stock Performance - As of January 8, the stock price increased by 2.02%, reaching 10.62 CNY per share, with a trading volume of 1.11 billion CNY and a turnover rate of 0.88%, resulting in a total market capitalization of 12.732 billion CNY [1]. - The stock has experienced a 7.49% increase over the last five trading days and a 2.02% increase over the last 20 days [2]. Group 2: Financial Performance - For the period from January to September 2025, the company reported a revenue of 7.923 billion CNY, reflecting a year-on-year growth of 0.61%, while the net profit attributable to shareholders decreased by 10.55% to 461 million CNY [2]. - Cumulative cash dividends since the company's A-share listing amount to 1.726 billion CNY, with 445 million CNY distributed over the past three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders increased to 54,400, a rise of 5.04%, with an average of 22,041 circulating shares per shareholder, which is a decrease of 4.79% [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 28.6504 million shares, an increase of 6.1171 million shares compared to the previous period [3].

Core Insights - Qualcomm's CEO Cristiano Amon highlighted the significant potential of the personal AI terminal market, particularly in smart wearable devices, predicting a future market size that could reach billions of units [1][3] Group 1: Market Potential - Amon stated that the next generation of personal AI devices will leverage edge AI, contextual awareness, and user data to understand user environments and intentions in real-time [3] - The expected shipment volume of these smart wearable devices is projected to reach between 10 million and 100 million units in the coming years, with a market size forecasted to reach billions of units [3] Group 2: Product Development - Amon emphasized that these devices will coexist with smartphones and will include various familiar wearable forms such as smart glasses, jewelry, pendants, rings, and brooches, creating opportunities for deep integration between technology and fashion [3] - Despite their small size, these devices require excellent energy efficiency, strong computing power, stable connectivity, and the ability to run local AI models [3] Group 3: Technological Advancements - Qualcomm's Snapdragon chips are capable of running models with billions of parameters on small wearable devices, and innovations in connectivity have been achieved, such as operating Wi-Fi at Bluetooth power levels to maintain continuous connection with smart agents [3]

Core Viewpoint - Zhejiang Borui Biopharmaceutical Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, aiming to provide comprehensive immunotherapy solutions for patients with autoimmune and inflammatory diseases, as well as tumor immunology diseases [3]. Financial Performance - The company reported revenues of RMB 1.26 billion, RMB 1.62 billion, and RMB 1.38 billion for the years 2023, 2024, and the first nine months of 2025, respectively [5]. - The net profit attributable to equity shareholders for the same periods was RMB 19.01 million, RMB 91.30 million, and RMB 121.84 million, with gross profit margins of 82.2%, 79.2%, and 74.4% [5]. - The company has eight commercialized products, including two innovative and six mature products, and ranked first among Chinese pharmaceutical companies in revenue from biologics for autoimmune diseases for two consecutive years starting in 2023 [3][5]. Company Background - Borui Biopharmaceutical was restructured from the biopharmaceutical division of Haizheng Pharmaceutical in January 2019 and is characterized as a fully integrated biopharmaceutical company [3]. - The board of directors consists of nine members, including two executive directors, four non-executive directors, and three independent non-executive directors, with key leadership including Chairman Xiao Suining and CEO Liu Min [8]. Investment and Valuation - The company has completed three rounds of financing from 2019 to 2022, with the latest round valuing the company at RMB 13.5 billion [5].

Group 1 - The core viewpoint of the article is that Borui Biotech is preparing for an IPO on the Hong Kong Stock Exchange with an estimated valuation of approximately 13.5 billion [1] - Borui Biotech is a comprehensive integrated biopharmaceutical company in China, with its history tracing back to the biopharmaceutical division of Haizheng Pharmaceutical [1] - The company underwent a restructuring into a limited liability company in 2019 and plans to convert into a joint-stock company by 2025, with major shareholders including PAG (44.62%) and Haizheng Pharmaceutical (39.62%) [1] Group 2 - Borui Biotech has eight commercialized products and is expected to generate significant revenue from 2023 to September 2025 [1] - In October 2024, Borui Biotech signed a promotion service agreement with Youshibi, obtaining exclusive CSO authorization [1] - In January 2025, the company entered into a licensing and collaboration agreement with Shandon Pharmaceuticals to develop and commercialize BR2251 [1]